The Supreme Court stayed the Fifth Circuit's mifepristone telehealth ban on May 14, preserving mail-order access while two justices raised the Comstock Act as a future threat.
A divided Supreme Court on May 14 granted an indefinite stay of a Fifth Circuit ruling that had banned mail-order and telehealth prescribing of mifepristone nationwide, keeping access to the medication abortion drug intact while underlying litigation proceeds [1]. The stay reversed the practical effect of the appellate court's May 1 order, which had shut down the primary distribution channel through which patients in states without abortion restrictions obtain the drug [2]. The Court did not grant certiorari and returned the matter to the Fifth Circuit for further proceedings [1].
The underlying case, Louisiana v. FDA, challenges the Food and Drug Administration's regulatory approvals that allow mifepristone to be prescribed via telehealth and dispensed through mail-order pharmacies [2]. Louisiana and aligned plaintiffs argue the FDA exceeded its authority in loosening those prescribing rules. Danco Laboratories and GenBioPro, the drug's manufacturers, are defending the FDA's framework alongside the agency [3]. The Fifth Circuit's May 1 ruling had sided with the challengers on the merits in substantial part, prompting an emergency application to the Supreme Court.
The significance of the stay extends beyond its immediate procedural effect. Justices Clarence Thomas and Samuel Alito each filed written dissents, signaling that at least two members of the Court view the majority's intervention as legally unjustified [1]. Alito's dissent characterized the order as an effort to circumvent the Court's 2022 ruling in Dobbs v. Jackson Women's Health Organization [1]. Thomas's dissent went further, arguing that the Comstock Act, a 19th-century federal obscenity statute, independently bars mailing mifepristone regardless of FDA approval status [3]. That argument, if adopted by a future majority, would operate as a nationwide prohibition on mail-order medication abortion without requiring any additional act of Congress.
The stay is indefinite but not permanent. The Fifth Circuit must now resolve the appeal on the merits, a process that could take months and will almost certainly produce another Supreme Court application from whichever side loses [2]. Observers expect the Comstock Act question Thomas raised to reappear in that briefing cycle, potentially forcing the full Court to address an issue it has so far declined to reach. Danco and GenBioPro will continue to distribute the drug through telehealth channels in the interim, preserving access for patients in states where clinic-based abortion remains available as well as those who rely on mail-order prescribing as their primary option [2] [3].